(CercleFinance.com) – Novo Nordisk announces the acquisition of ocedurenone for the treatment of uncontrolled hypertension from KBP Biosciences. The operation involves an amount of up to 1.3 billion US dollars.
Ocedurenone is an orally administered, small-molecule, nonsteroidal mineralocorticoid receptor antagonist (nsMRA) currently being investigated in the Phase 3 CLARION-CKD trial in patients with uncontrolled hypertension and chronic kidney disease. (IRC) advanced.
Uncontrolled hypertension is when a person’s blood pressure remains high despite taking two or more hypotensive medications.
‘With its expected benefit-risk profile, ocedurenone has best-in-class potential in the treatment of uncontrolled hypertension and could help address a major unmet medical need in people living with cardiovascular disease and chronic kidney disease.’ said Martin Holst Lange, Executive Vice President and Head of Development at Novo Nordisk.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
